Our Heritage

For more than 65 years, Lantheus has been advancing patient care by learning, adapting and making advancements across the healthcare spectrum. We’ve been an instrumental pioneer in the field of medical imaging and, today, we’re reaching further still with novel therapeutics and AI technologies. And we’ll continue to forge ahead with new solutions to new problems—always knowing that someone’s health is in our hands.

Our Broad Portfolio Features:

Precision Diagnostics that Find and Follow diseases in non-oncologic conditions

Radiopharmaceutical Oncology diagnostic and therapeutic products that Find, Fight and Follow® cancer

Strategic Partnerships that empower precision medicine through the use of biomarkers and digital solutions

Our History

Lantheus has a rich history of transformative mergers, acquisitions and innovative product launches. Explore our evolution from founding as New England Nuclear in 1956 to today.

1956

Founded

1967

FDA Approval

1981

DuPont Purchases NEN

1990

FDA Approval

1991

DuPont Forms Venture with Merck Called DuPont Merck

1998

DuPont Buys Merck’s Interest, Becomes DuPont Pharmaceuticals

2001

Bristol Myers Squibb Co. Purchases DuPont Pharmaceuticals

2001

FDA Approval

2008

BMS Sells BMS Medical Imaging to Avista Capital Partners, Lantheus Medical Imaging Launched

2008

FDA Approval for SC

2015

IPO on Nasdaq

2016

FDA Approval for Tablets

2018

FDA Approval

2020

Lantheus Merges with Progenics

2021

FDA Approval

2021

FDA Clearance

2022

Corporate Rebrand

2022

DEFINITY Manufacturing Site Approval – Billerica

2022

In-licenses PNT2002 and PNT2003 – two late-stage radiotherapeutic product candidates from POINT Biopharma

2023

Acquires Cerveau Technologies – including MK-6240, novel PET imaging agent for Alzheimer’s Disease

Our Partnerships

We seek partnerships that align with our strategy to solve unmet patient needs through innovation. It’s an entrepreneurial spirit that extends to academic institutions, joint ventures and investment partners. Our openness to creative collaboration makes Lantheus an ideal partner for organizations that share our passion for improved therapeutic, diagnostic and AI technology options for healthcare providers and patients.